Hepatocellular carcinoma.
Primary hepatocellular carcinoma is one of the 10 most common tumours, and the most common primary liver malignancy, in the world. In the majority of cases, it occurs against a background of hepatitis B or C viral infection and/or liver cirrhosis, and is associated with a dismal prognosis of a few months. Current treatments in routine clinical practice are surgical resection and liver transplantation, but these therapies are applicable to only a small proportion of patients and prolongation of survival is restricted. Other treatment options include intra-arterial chemotherapy, transcatheter arterial chemoembolisation, percutaneous ethanol injection, cryotherapy, thermotherapy, proton therapy, or a wide range of their possible combinations. The current lack of definitive data, however, limits the use of these therapies. Another option is gene therapy, which although in its infancy at the present time, may have a significant role to play in the future management of hepatocellular carcinoma.
Badvie
S
S
The Guy's, King's College & St Thomas' Medical School, London, UK.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D015415:Biomarkers; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D003287:Contrast Media; D006498:Hepatectomy / Q000379:methods; D006525:Hepatitis, Viral, Human / Q000150:complications; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D016031:Liver Transplantation / Q000379:methods; D011379:Prognosis
D000970:Antineoplastic Agents; D015415:Biomarkers; D003287:Contrast Media